How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial involving 7,020 patients with type 2 diabetes and established cardiovascular (CV) disease, empagliflozin given in addition to standard of care reduced the risk of CV death by 38% versus placebo (hazard ratio [HR] 0.62 [95% CI 0.49, 0.77]). This exploratory mediation analysis assesses the extent to which treatment group differences in covariates during the trial contributed to CV death risk reduction with empagliflozin. RESEARCH DESIGN AND METHODS: Effects of potential mediators, identified post hoc, on the HR for CV death with empagliflozin versus placebo were analyzed by Cox regression models, with treatment group adjusted for the baseline value of the variable and its change from baseline or updated mean (i.e., considering all prior values), each as a time-dependent covariate. HRs were compared with a model without adjustment for covariates. Multivariable analyses also were performed. RESULTS: Changes in hematocrit and hemoglobin mediated 51.8% and 48.9%, respectively, of the effect of empagliflozin versus placebo on the risk of CV death on the basis of changes from baseline, with similar results in analyses on the basis of updated means. Smaller mediation effects (maximum 29.3%) were observed for uric acid, fasting plasma glucose, and HbA1c. In multivariable models, which incorporated effects of empagliflozin on hematocrit, fasting glucose, uric acid, and urine albumin:creatinine ratio, the combined changes from baseline provided 85.2% mediation, whereas updated mean analyses provided 94.6% mediation of the effect of empagliflozin on CV death. CONCLUSIONS: In this exploratory analysis from the EMPA-REG OUTCOME trial, changes in markers of plasma volume were the most important mediators of the reduction in risk of CV death with empagliflozin versus placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both have been identified as important determinants of the heart failure benefits of these drugs in trials of patients with type 2 diabetes.”
From Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial (2021) · cites this paper as [32]
In the citing paper
“Those that appear particularly plausible include effects on volume status, natriuresis, expansion of red blood cell mass, and myocardial energetics (34,36,59,62,64).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [59]
In the citing paper
“Thus, the mechanisms by which SGLT2 inhibitors reduce the risk for HF are not attributable to improved glycemic control (59).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [59]
Citations
Cites
Baron, R. M., & Kenny, D. A. (1986) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.51.6.1173 · Cited by 91,532 · cited 2×
“A traditional mediation analysis as originally proposed by Baron and Kenny (12) was used, taking the time-dynamic evolvement of both the potential mediators and the outcome CV death into account.”
Method(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Introduction to Statistical Mediation Analysis
MacKinnon, D. P. (2012) · doi:10.4324/9780203809556 · Cited by 5,618
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationUric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Self-citationCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329 · cited 1×
“Moreover, only variablesmeasured during the trial could be examined, and in addition to the potential mediators we investigated, other variables such as reductions in glomerular hyperfiltration (35), reductions in arterial stiffness and vascular resistance (36), direct cardiac effects through reductions in myocardial…”
BackgroundSelf-citationLow Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155 · cited 1×
“Therefore, many participants in this trial likely had unrecognized left ventricular dysfunction, particularly diastolic dysfunction, which may eventually lead to clinical heart failure with preserved ejection fraction (25).”
Background
Research works printed but not linked: 2
- Fitchett, Further exploration of the cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease in EMPA-REG OUTCOME, J Am Coll Cardiol
- Boehringer Ingelheim. Empagliflozin (Jardiance®) to be studied in chronic kidney disease. 2017. Available from https://www.boehringer-ingelheim.com/press-release/empagliflozin-be-studied-chronic-kidney-disease. Accessed 6 September 2017
Cited by
Items 401–500 of 762
Mee, X. C., Lim, G. K., Ibrahim, R., Pham, H. N., Abdelnabi, M. H., Allam, M., Bcharah, G., Tan, M. C., Barry, T., Farina, J., et al. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf026 · Cited by 12
McHugh, K. R., DeVore, A. D., Mentz, R. J., Edmonston, D. L., Green, J. B., & Hernandez, A. F. (2018) · Clinical Cardiology · doi:10.1002/clc.23054 · Cited by 13
“To further support the importance of the diuretic and natriuretic effects of SGLT2 inhibitors, a recent exploratory analysis of the EMPA-REG OUTCOME trial found markers of plasma volume, mainly hemoglobin and hematocrit, to be the most important mediators of reduction of CV death with empagliflozin.(24) Nonhemodynamic…”
ResultTanaka, A., Toyoda, S., Imai, T., Shiina, K., Tomiyama, H., Matsuzawa, Y., Okumura, T., Kanzaki, Y., Onishi, K., Kiyosue, A., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01369-5 · Cited by 13
Tye, S. C., de Vries, S. T., Wanner, C., Denig, P., & Heerspink, H. J. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.786706 · Cited by 12
“This finding is consistent with previous mediation analyses demonstrating that the change in hemoglobin explains a substantial proportion of the benefit of SGLT2 inhibitors on kidney and heart failure outcomes (Inzucchi et al., 2018; Li et al., 2020a; Li et al., 2020b).”
ResultSelf-citationThe Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney
Gronda, E., Vanoli, E., Iacoviello, M., Caldarola, P., Gabrielli, D., & Tavazzi, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911987 · Cited by 13
“The persistence of higher hematocrit after SGLT2is administration proved to favorably impact patient outcomes in investigated diabetic and HF populations [21,47].”
BackgroundLiu, G., Zhong, X., Zheng, J., Zhang, J., Kong, W., Hu, X. F., Min, J., Xia, W., Zeng, T., & Chen, L. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01391-8 · Cited by 13
Diabetes medications and cardiovascular disease: at long last progress
Lupsa, B. C., & Inzucchi, S. E. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000400 · Cited by 12
Self-citationYandrapalli, S., Jolly, G. P., Horblitt, A. M., Pemmasani, G., Sanaani, A., Aronow, W. S., & Frishman, W. H. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000308 · Cited by 14
Koomen, J. V., Stevens, J., & Heerspink, H. J. L. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14318 · Cited by 13
“Favourable effects of dapagliflozin have been demonstrated on other cardiorenal risk markers including systolic blood pressure (SBP), haematocrit (HCT), albuminuria and uric acid (UA).(8,9) The Dapagliflozin Effect on Cardiovascular Events—Thrombolysis in Myocardial Infarction (DECLARE-TIMI) 58 trial observed long-ter…”
BackgroundRusso, G. T., Monami, M., Perseghin, G., Avogaro, A., Filardi, P. P., Senni, M., Borghi, C., & Maggioni, A. P. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01045-7 · Cited by 12
Starr, J. A., Pinner, N. A., Lisenby, K. M., & Osmonson, A. J. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2527 · Cited by 15
Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease
Almaimani, M. K., Sridhar, V. S., & Cherney, D. Z. I. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000724 · Cited by 13
“Insights from a mediation analysis of the EMPAREG OUTCOME Trial.”
BackgroundInfluentialSenior, P. A. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.09.001 · Cited by 12
Wang, X., He, M., Jin, D., Sun, C., & Lu, H. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01446-1 · Cited by 12
“These effects might involve modulation of sodium balance, enhancement of energy homeostasis, and alleviation of cellular stress, or they could be triggered by alterations in renal hemodynamics [8, 40].”
BackgroundBeernink, J. M., Jongs, N., Mosterd, C. M., Scholtes, R. A., Caldwell‐McGee, A., Casillas, D. I., Driscoll, L. M., Greasley, P. J., Karlsson, C., Hammarstedt, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16478 · Cited by 11
Nephroprotective Mechanisms of SGLT2i: Beyond the Glucose-Lowering Effect
Mazzieri, A., & Marcon, L. M. R. (2025) · Biomedicines · doi:10.3390/biomedicines13092123 · Cited by 13
“An exploratory analysis of the EMPA-REG OUTCOME [47] suggested that variations in uric acid levels contributed to a minor extent to a reduction in cardiovascular death rate.”
Next-Generation SGLT2 Inhibitors: Innovations and Clinical Perspectives
Man, D. E., Duda-Seiman, D. M., & Dragan, S. R. (2025) · Biomedicines · doi:10.3390/biomedicines14010081 · Cited by 11
“…originally developed as glucose-lowering agents, large randomized clinical trials have demonstrated robust cardiovascular benefits, including reductions in heart failure hospitalization and cardiovascular mortality, across diverse patient populations, including individuals without diabetes [14].”
Vilsbøll, T., Ekholm, E., JOHNSSON, E. K., García‐Sánchez, R., Dronamraju, N., Jabbour, S. A., & Lind, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13981 · Cited by 12
Schwarz, Y., Klein, P., & Lev-Shalem, L. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02174-0 · Cited by 13
Scheen, A. J. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101508 · Cited by 12
Abdul‐Ghani, M. A., Migahid, O., Megahed, A., Singh, R., Fawaz, M., DeFronzo, R. A., & Jayyousi, A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13546 · Cited by 13
“Of note, the increase in haematocrit has been postulated to account for 50% of the cardiovascular benefit of empagliflozin in the EMPA-REG study.(16).”
BackgroundCanagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program
Wang, K. M., Li, J., Bhalla, V., Jardine, M., Neal, B. C., de Zeeuw, D., Fulcher, G., Perkovic, V., Mahaffey, K. W., & Chang, T. I. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.247 · Cited by 12
SGLT2 Inhibitors: A Broad Impact Therapeutic Option for the Nephrologist
Granata, A. R. M., Pesce, F., Iacoviello, M., Anzaldi, M., Amico, F., Catalano, M. R., Leonardi, G., Gatta, C., Costanza, G., Corrao, S., et al. (2022) · Frontiers in Nephrology · doi:10.3389/fneph.2022.867075 · Cited by 12
Haematometabolism rewiring in atherosclerotic cardiovascular disease
Yvan‐Charvet, L., Barouillet, T., & Borowczyk, C. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01108-9 · Cited by 10
“…haematocrit levels that has been observed after lowering of blood glucose levels with inhibitor treatment might be a mediator of the >50% reduction in the risk of death from CVD with empagliflozin in patients with type 2 diabetes and established CVD, as observed in the EMPA-REG OUTCOME trial 132 .”
Innovative therapeutics for renoprotection: Where we are
Cortinovis, M., Perico, N., & Remuzzi, G. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100060 · Cited by 10
Pollock, C. A., & Neuen, B. L. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.02.006 · Cited by 11
Bariatric surgery and kidney disease outcomes in severely obese youth
Bjornstad, P., Nehus, E. J., & van Raalte, D. H. (2020) · Seminars in Pediatric Surgery · doi:10.1016/j.sempedsurg.2020.150883 · Cited by 11
Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
Dimova, R. B., & Tankova, T. I. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1298-4205 · Cited by 12
Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes
Siasos, G., Bletsa, E., Stampouloglou, P. K., Paschou, S. Α., Oikonomou, E. K., Tsigkou, V., Antonopoulos, A. S., Vavuranakis, M., & Tousoulis, D. M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201109110107 · Cited by 10
SGLT2 inhibitors: a new pillar of the heart failure regimen
DeSa, T. B., & Gong, T. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2204133 · Cited by 11
van Ruiten, C. C., Hesp, A. C., & van Raalte, D. H. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.03.031 · Cited by 11
Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studies
Yvan‐Charvet, L., & Cariou, B. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000505 · Cited by 10
Ferrannini, G., & Rydén, L. (2018) · Clinical Science · doi:10.1042/cs20171374 · Cited by 10
Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors
Vaduganathan, M., & Januzzi, J. L. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.08.008 · Cited by 11
An evaluation of empagliflozin and it’s applicability to hypertension as a therapeutic option
Herat, L. Y., Matthews, V. B., Magno, A. L., Kiuchi, M. G., Carnagarin, R., & Schlaich, M. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1751815 · Cited by 10
“In contrast, changes in some traditional CV risk factors such as obesity, BP, lipids, and renal function appeared to make negligible contributions [34].”
BackgroundMartínez, J. J. G., GARGALLO-FERNANDEZ, M. A., Sanz-Pastor, A. G., Antón-Bravo, T., Brito-Sanfiel, M. Á., & WONG-CRUZ, J. E. M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072275 · Cited by 10
“In two exploratory analyses from the EMPA-REG OUTCOME trial and the CANVAS program, changes in hematocrit were the most important mediators of risk reduction of CV death with empagliflozin and heart failure with canagliflozin, respectively [42,43].”
MethodInteraction between sodium-glucose co-transporter 2 and the sympathetic nervous system
Azzam, O., Matthews, V. B., & Schlaich, M. P. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000767 · Cited by 10
“The offloading of sodium and water, and the associated hemoconcentration, might in part explain the early separation in HHF Kaplan-Meier curves in SGTL2 inhibitor cardiovascular outcomes trials, perhaps through reduction in cardiac preload [23,24,44].”
Koufakis, T., Vas, P. R. J., Maltese, G., & Kotsa, K. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac116 · Cited by 11
“5 been shown to be mainly dependent on changes in markers of plasma volume (3), and apply to a wide range of patients, regardless of the history of CV disease.”
BackgroundMcMurray, J. J. V., Solomon, S. D., Lock, J. P., Massaro, J. M., Zhu, F., Zhou, W., Skali, H., Lewis, E. F., Freeman, M. W., & Halvorsen, Y. C. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15394 · Cited by 9
Sodium-glucose co-transporter-2 inhibitors: know the patient and the drugs
Lim, L., & Chan, J. C. N. (2019) · Hong Kong Medical Journal · doi:10.12809/hkmj195089 · Cited by 9
Bonnet, F., Vaduva, P., Halimi, J., Dosda, A., Ducluzeau, P., Koppe, L., & Fauchier, L. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02930-2 · Cited by 9
“Consistently, a link between changes in hematocrit values and the effects of empagliflozin on cardiovascular mortality [37] and heart failure outcomes [38] was also observed in the EMPA-REG OUTCOME trial.”
Nguyen, A., Khafagy, R. T. M., Hashemy, H., Kuo, K. H. M., Roshandel, D., Paterson, A. D., & Dash, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1146099 · Cited by 9
“, insulin and sodium glucose co-transporter 1 inhibitors), which can impact both glycemia and erythrocytosis (19, 37) TABLE 1 Cohort details for Mendelian Randomization (MR) analyses.”
BackgroundInduction of erythropoietin by dietary medium-chain triacylglycerol in humans
Kanta, J. M., Lundsgaard, A., Schaufuss, A., Kleinert, M., Kiens, B., & Fritzen, A. M. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00415.2024 · Cited by 9
Possible Mechanisms of Action of SGLT2 Inhibitors in Heart Failure
Martins, C. N. G., Bau, A. A., da Silva, L. M., & Coelho‐Filho, O. R. (2021) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20210007 · Cited by 12
Kurczyński, D., Hudzik, B., Jagosz, M., Zabierowski, J., Nowak, J. U., Tomasik, A. R., Bądziński, A., Rozentryt, P., & Gąsior, M. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9070225 · Cited by 10
“In addition, studies showed that increased red blood cell count and hemoglobin concentrations were potent mediators of reduced HF hospitalizations and cardiovascular deaths when SGLT2 inhibitors were used [76,77].”
BackgroundSubramanian, A., Gokhale, K. M., Sainsbury, C. A. R., Nirantharakumar, K., & Toulis, K. A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14858 · Cited by 11
Huang, Q., Zou, X., Gao, P., Han, X., Zhou, X., & Ji, L. (2023) · Journal of Global Health · doi:10.7189/jogh.13.04032 · Cited by 9
Ito, D., Inoue, K., Sumita, T., Hamaguchi, K., Kaneko, K., Yanagisawa, M., Inukai, K., Inoue, I., Noda, M., & Shimada, A. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3491w · Cited by 9
“Enhanced erythropoiesis could be a complementary mechanism to the hemodynamic changes reflected by increases in hematocrit and hemoglobin in patients treated with SGLT2 inhibitors [22].”
Marre, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13975 · Cited by 11
“sis performed in the EMPA-REG study concluded that approximately 50% of the benefits attributable to empagliflozin were related to the reduction in extracellular volume.(93) The drop in BP observed in that study was primarily attributable to volume reduction, hence the”
MethodLund, S. S., Sattar, N. A., Salsali, A., Neubacher, D., & Ginsberg, H. N. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14534 · Cited by 9
“46 Consequently, even if caused by volume contraction, any increase in atherogenic lipid fractions, such as LDL-cholesterol, did not offset a more general beneficial effect in reducing cardiovascular events, including myocardial infarction, with empagliflozin in EMPA-REG OUTCOME.”
BackgroundYandrapalli, S., Malik, A. H., Horblitt, A. M., Pemmasani, G., Aronow, W. S., & Frishman, W. H. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000311 · Cited by 10
“A post-hoc exploratory mediation analysis of the EMPA-REG OUTCOME trial, which sought to identify potential mechanisms underlying the 38% reduction in the risk of CV death with empagliflozin, found that changes in markers of plasma volume (hematocrit and hemoglobin) appeared to be the variables with the largest impact…”
MethodImpact of currently used anti-diabetic drugs on myoendothelial communication
Ding, H., Ye, K., & Triggle, C. R. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.11.002 · Cited by 9
Diving into the Unknown: Sodium–Glucose Cotransporter-2 Inhibitors in Heart Failure without Diabetes
Seferovic, P. M., Seferović, J. P., & Polovina, M. M. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1500 · Cited by 9
SGLT-2 inhibitors in heart failure: a new therapeutic avenue
Vaduganathan, M., & Butler, J. (2019) · Nature Medicine · doi:10.1038/s41591-019-0647-4 · Cited by 9
How Do SGLT-2 Inhibitors Work to Prevent Heart Failure?
Vaduganathan, M., Claggett, B. L., & Solomon, S. D. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.11.009 · Cited by 9
Schumacher, K. A., & Gosmanov, A. R. (2022) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096221111774 · Cited by 8
Minimizing Metabolic and Cardiac Risk Factors to Maximize Outcomes After Liver Transplantation
Schmidt, K., Spann, A., Khan, M. Q., Izzy, M. J., & Watt, K. D. S. (2023) · Transplantation · doi:10.1097/tp.0000000000004875 · Cited by 10
“50,51 In a meta-analysis of nontransplant patients with DM receiving either SGLT2i or GLP1RAs compared with placebo, a significant risk reduction of 14% in MACE was seen only among patients with CVD at baseline.”
Kugathasan, L., Sridhar, V. S., Lytvyn, Y., Lovblom, L. E., Perkins, B. A., Advani, A., & Cherney, D. Z. I. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111764 · Cited by 8
Klabuzai, Á., Bekő, V., Sütő, Z., Horváth, M., Wagner, Z., Vágási, K., Pfeil, V., Süle, M., Grósz, G., Wittmann, I., et al. (2025) · Antioxidants · doi:10.3390/antiox14030289 · Cited by 8
“In a post hoc analysis of EMPA-REG OUTCOME, changes in hematocrit alone were estimated to account for approximately 52% of empagliflozin’s cardiovascular benefit [24].”
Incidence and clinical outcomes of pneumonia in persons with down syndrome in the United States
Janoff, E. N., Tseng, H. F., Nguyen, J. L., Alfred, T., Vietri, J., McDaniel, A., Chilson, E. L., Yan, Q., Malhotra, D., Istúriz, R., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.063 · Cited by 9
SGLT2 Inhibition in Heart Failure: Clues to Cardiac Effects?
Savage, P., Dixon, L., Grieve, D., & Watson, C. J. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000637 · Cited by 8
“22 Interestingly, these effects on erythrocyte mass and plasma cell volume are not noted when compared to standard diuretics such as hydrochlorothiazide.”
Macrovascular Risk Equations Based on the CANVAS Program
Willis, M. S., Asseburg, C., Slee, A. E., Nilsson, A., & Neslusan, C. A. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01001-0 · Cited by 8
Different Sodium-Glucose Cotransporter-2 Inhibitors: Can They Prevent Death?
Mukhopadhyay, P., Sanyal, D., Chatterjee, P., Pandit, K., & Ghosh, S. K. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.05.005 · Cited by 8
Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure
Lytvyn, Y., Scholtes, R. A., Boorsma, E. M., Sridhar, V. S., Kugathasan, L., Liu, H., Lovblom, L. E., Handoko, M. L., Mosterd, C. M., Floras, J. S., et al. (2025) · Physiological Reports · doi:10.14814/phy2.70275 · Cited by 7
Metabolomics Insights into the Benefits of SGLT2 Inhibitors in Type 2 Diabetes
Kyriakidou, A., Koufakis, T., Gika, H., & Kotsa, K. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497906 · Cited by 13
The effect of the four pharmacological pillars of heart failure on haemoglobin level
Hullon, D., Taherifard, E., & AlSaraireh, T. H. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001773 · Cited by 7
“In a secondary analysis of the EMPA-REG OUTCOME Trial, mediators contributing to the reduction observed in mortality due to cardiovascular causes with the use of empagli fl ozin were explored [109] .”
MethodLi, Z., Li, A., Sun, D., & Shu, Y. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2505154 · Cited by 7
“These effects could be associated with various mechanisms, including the regulation of sodium balance, maintenance of energy homeostasis, reduction of cellular stress, enhancement of endothelial function, and promotion of vasodilation [28–31].”
BackgroundErythropoietic response to oral iron with sodium-glucose co-transporter 2 inhibitors
Marques, P. S., Matias, P., Travlos, C. K., Angélico‐Gonçalves, A., Diniz, H., Vasques‐Nóvoa, F., Packer, M., Friões, F., Tsoukas, M. A., Mavrakanas, T. A., et al. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02685-6 · Cited by 8
Bauduceau, B., Bordier, L., Bringer, J., Chabrier, G., Charbonnel, B. H., Cosson, E., Darmon, P., Detournay, B., Fontaine, P., Gourdy, P., et al. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30056-2 · Cited by 20
“[15] Inzucchi SE, Zinman B, Fitchett D, et al.”
BackgroundSmetana, G. W., Nathan, D. M., Dugdale, D. C., & Burns, R. B. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0946 · Cited by 8
Tanaka, A., Imai, T., Toyoda, S., Sugimoto, K., Yoshida, R., Furuta, M., Node, K., & the PROTECT Investigators (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01129-3 · Cited by 8
Evolution of Glucose-Lowering Drugs for Type 2 Diabetes
Krentz, A. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812019-4.00033-7 · Cited by 8
Nashawi, M., Sheikh, O., Battisha, A., Mir, M., & CHILTON, R. J. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09996-y · Cited by 7
Krämer, B. K., Hauske, S. J., CHILTON, R. J., Mann, J. F. E., Gullestad, L. L., FITCHETT, D. H., Mattheus, M., Steubl, D., & Wanner, C. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108588 · Cited by 7
Self-citationKobayashi, K., Toyoda, M., & Hatori, N. (2019) · Obesity Medicine · doi:10.1016/j.obmed.2019.100088 · Cited by 7
Koufakis, T., Papazafiropoulou, A. K., Makrilakis, K., & Kotsa, K. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07249-0 · Cited by 7
SGLT-2 Inhibitor Use in Heart Failure: A Review for Nurses
March, K. L., Lukas, J. G., Berei, T. J., Shah, S. P., & Cave, B. E. (2022) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0000000000000401 · Cited by 7
Dapagliflozin in Heart Failure: New Frontiers
Tromp, J., & Collins, S. P. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1633 · Cited by 7
Liang, B., Zhao, Y.-X., & Gu, N. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01004-9 · Cited by 7
“Remember, the dose of empagliflozin is only 10 mg or 25 mg once daily in clinical trials [2, 10] , translating less than 3 mg/kg/day for rats.”
BackgroundLimitations of Natriuretic Peptide Levels in Establishing SGLT-2 Inhibitors for Heart Failure Care
Velazquez, E. J., & Reinhardt, S. W. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.538 · Cited by 7
Ferrannini, G., Musella, F., Benson, L., Valente, V., Lindberg, F., Boccalatte, M., Cabrera, C. C., Dahlström, U., Lund, L. H., Stolfo, D., et al. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag063 · Cited by 6
Sarabhai, T., & Kostev, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70057 · Cited by 6
“6 Thus, the interaction between SGLT2 inhibitors and iron metabolism in type 2 diabetes remains an evolving area of interest.”
CVOTs: What did the endocrinologist learn?
Valensi, P. E., & Prévost, G. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107947 · Cited by 6
Inagaki, N., Nishimoto, T., Nishiya, Y., & Nitta, D. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2107200 · Cited by 7
“SGLT2 inhibitors in univariable and multivariable models [41].”
BackgroundThe Emerging Role of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure
Gitto, M., Villaschi, A., Federici, M., Condorelli, G., & Stefanini, G. G. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230217143324 · Cited by 6
Nakatani, D., Dohi, T., Hikoso, S., Tanaka, A., Nanasato, M., Shimizu, W., Node, K., Sakata, Y., & on behalf of the CANDLE Trial Investigators (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001430 · Cited by 6
“Regarding the relationship between hematopoiesis associated with SGLT2i and long-term outcomes, Inzucchi et al23 demonstrated using exploratory mediation analysis in the EMPA-REG OUTCOME Trial that there was a significant Variable t value P b SE b Lower Upper (a) Hematocrit difference (24 wk minus…”
MethodKishimoto, S., Higashi, Y., Imai, T., Eguchi, K., Fukumoto, K., Tomiyama, H., Maemura, K., Tanaka, A., Node, K., the PROTECT investigators, et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01856-x · Cited by 6
“[11] showed that changes in hematocrit and hemoglobin levels in the EMPA-REG OUTCOME trial might be major mediators of empagliflozin-induced decreases in the incidence of cardiovascular events.”
BackgroundMunde, M. K., Kulkarni, N. S., Sen, A. K., & Sen, D. B. (2023) · INDIAN DRUGS · doi:10.53879/id.60.06.13038 · Cited by 6
Patoulias, D., Eid, A. H., & Rizzo, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108630 · Cited by 6
Shared decision-making approach to type 2 diabetes management
MacDonald, B. J., McCormack, J. P., & Turgeon, R. D. (2024) · Canadian Family Physician · doi:10.46747/cfp.7005310 · Cited by 7
Extrarenal Benefits of SGLT2 Inhibitors in the Treatment of Cardiomyopathies
Yerra, V. G., & Connelly, K. A. (2024) · Physiology · doi:10.1152/physiol.00008.2024 · Cited by 7
Elliott, J., & Oyama, M. A. (2024) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.13472 · Cited by 8
Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
Darwish, D., Kumar, P., Urs, K., & Dave, S. (2025) · Cells · doi:10.3390/cells14120919 · Cited by 6
“…EMPIRE HF RENAL trial, treatment with empagliflozin resulted in significant reductions in extracellular volume and plasma volume [59], while a post hoc analysis of EMPA-REG OUTCOME showed a hemoconcentration effect to have contributed significantly to the reduction in cardiovascular mortality [60].”
Rados, D. R. V., Viecceli, C., Pinto, L. C. F., Gerchman, F., Leitão, C. B., & Gross, J. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-69738-w · Cited by 7
Oh, M., Choi, J. H., Kim, S., Lee, P. H., Ahn, J., Lee, S., Moon, D. H., & Lee, C. W. (2021) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001429 · Cited by 6
Onyali, C. B., Anim-Koranteng, C., Shah, H. E., Bhawnani, N., Ethirajulu, A., Alkasabera, A., & Mostafa, J. A. (2021) · Cureus · doi:10.7759/cureus.17452 · Cited by 9
Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy
Siebel, S., Galderisi, A., Patel, N. S., CARRIA, L. R., Tamborlane, W. V., & Sherr, J. L. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0356 · Cited by 6
Pharmacotherapeutic principles of fluid management in heart failure
Narasimhan, B., Aravinthkumar, R., Correa, A. A., & Aronow, W. S. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1850694 · Cited by 7
Beneficial effects of empagliflozin on hematocrit levels in a patient with severe anemia
Budzianowski, J., Rzeźniczak, J., Hiczkiewicz, J., Kasprzak, D., Winnicka-Zielińska, A., Musielak, B., Pieszko, K., & Burchardt, P. (2021) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-021-00417-5 · Cited by 6
Matsubayashi, Y., Yoshida, A., Suganami, H., Oe, M., Sato, T., Yaguchi, Y., Fujihara, K., Yamada, T., Tanaka, S., Kaku, K., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14836 · Cited by 6
“Increases in Hb in relation to enhanced oxygen supply in circulating plasma might contribute to the SGLT2 inhibitor-induced prevention of cardio-renal events in T2D.3,4 It has been reported, however, that not only anaemia, but also polycythaemia increases the risk of mortality and worsening heart failure.5 A recent st…”
BackgroundInfluential
Metadata
- Authors
- Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., Hantel, S., Bluhmki, E., & Lachin, J. M.
- Affiliations
- Yale University (US)
- Mount Sinai Hospital (CA)
- St. Michael's Hospital (CA)
- Universitätsklinikum Würzburg (DE)
- Istituto di Fisiologia Clinica (IT)
- University of Freiburg (DE)
- Boehringer Ingelheim (Norway) (NO)
- Boehringer Ingelheim (Germany) (DE)
- George Washington University (US)
- Corresponding author
- Inzucchi, Silvio E.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-04
- Volume
- 41
- Issue
- 2
- Pages
- 356-363
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2772204795
- Cited by
- 740
- References
- 33
- Citations by year
- 2026: 33 · 2025: 48 · 2024: 71 · 2023: 83 · 2022: 103 · 2021: 109 · 2020: 139 · 2019: 96 · 2018: 56
- FWCI
- 62.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Eisai
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- empagliflozin, cardiovascular mortality, mediation analysis, type 2 diabetes, EMPA-REG OUTCOME trial, hematocrit, hemoglobin, plasma volume, uric acid, fasting blood glucose, HbA1c, urine albumin-creatinine ratio, SGLT2 inhibitors
- MeSH terms
- Adult, Aged, Benzhydryl Compounds, Blood Glucose, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Dose-Response Relationship, Drug, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Placebos, Risk Factors, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.